Genmab — September 2025
-
Is Now a Good Time to Buy Danish Stocks?https://proinvestor.com/boards/128483
-
Fra BSInvest: "Bruddet gennem 1.800 DKK signalerer styrke og bekræftelse af den uptrend som blev indikeret fornyligt. Bemærk dog at bruddet sker under moderat omsætning. Overvåg dagens lukning for bekræftelse. Hvis lukkekursen bliver over kurs 1.800 kan aktien teste 1.900 DKK i løbet af næste uge.
Det kræver dog et stigende momentum". -
TECVAYLI
and DARZALEX FASPRO-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma https://www.prnewswire.com/news-releases/tecvayli-and-darzalex-faspro-based-induction-treatment-demonstrates-promising-rates-and-depths-of-response-in-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-302561499.html -
Genmab-partner præsenterer lovende resultater fra kombinationsstudie
i dag kl. 14:55 ∙ MarketWireGenmabs amerikanske partner Johnson & Johnson har præsenteret positive resultater fra et studie, der kombinerer kræftmidlerne Tecvayli og Darzalex Faspro.
Studiet er gennemført i transplantationsegnede patienter med nydiagnosticeret knoglemarvskræft og demonstrerer, at kombinationen har meningsfuld effekt, skriver Johnson & Johnson i en meddelelse.
-
Genmab modtager trinvist stigende royalties på 12-20 pct. fra Johnson & Johnsons salg af Darzalex. Også Tecvayli har Genmab andel i, om end det skæpper noget mindre i kassen, da selskabet kun får midt encifrede procenter af salget.
.\˙ MarketWire
-
-
Sådan har de danske biotech aktier performet den seneste måned https://proinvestor.com/investornyt/1363579/sadan-har-de-danske-biotech-aktier-performet-den-seneste-maned
-
Brud opad gennem loftet af faldende trendkanal på mellemlang sigt, med stærk prisstigning siden rektangel-formationens brud ved 1506 DKK (mål på 1650 og 1754 opfyldt). RSI over 70 viser stærk positiv momentum, stigende optimisme og pris over kritiske støtteniveauer. Analytikere ser 31,68% upside-potentiale.
-
Nu kunne jeg godt tænke mig at @Stockbull kom på banen. - Han har om nogen ramt aktien i uptrends tider. Og her skulle vi jo befinde os nu...
-
Guggenheim analyst Michael Schmidt upgraded Genmab (GMAB) to Buy from Neutral with a $43 price target, citing increased conviction in Epkinly’s outlook https://www.tipranks.com/news/the-fly/genmab-upgraded-to-buy-at-guggenheim-on-royalty-revenue-upside-potential-thefly
-
Genmab: Major Shareholder Announcement https://proinvestor.com/investornyt/1364289/major-shareholder-announcement
-
Genmab får købsanbefaling fra amerikansk børshus: Ser potentiale på 50 pct. https://proinvestor.com/investornyt/1364272/genmab-far-kobsanbefaling-fra-amerikansk-borshus-ser-potentiale-pa-50-pct
-
Genmab får ny storaktionær https://proinvestor.com/investornyt/1364304/genmab-far-ny-storaktionaer
-
Orbis was set up in 1989. Our founder Allan Gray believed that a fundamental, contrarian long-term approach offered great potential. If he applied it successfully, he could help people grow their money meaningfully over time.
Until 2015, our Funds were only available to institutions, like pension funds, with millions to invest. But we wanted to make investing in funds simpler and more accessible for everyone.
-
Læs mere om den nye storaktionær: https://www.orbis.com/uk/individual/about-us/about-us
men lidt stoppen op er almindeligt.
Du plejer at ramme den temmelig godt, kan man roligt sige.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind